LET US ASCEND THE WALL AGAINST DENGUE (THE DISEASE OF POVERTY)
Keywords:Desquamation, Thrombocytopenia, Hemorrhage, Hypotension, Intracutaneous Langerhans cells, Apoptosis, Fluorescent antibody, Vasculopathy, Thrombopathy
The origin of the word dengue is not clear. It is believed “Cramp like seizure caused by evil spirit”. In Spanish, dengue were said to have the posture and gait of a dandy, and the disease was known as ”Dandy Fever”. Benjamin Rush, Coined the term "Break bone fever" because of the symptoms of myalgia and arthralgia.
260 peer-reviewed articles referred to dengue as "Poor man's disease. It is a severe life-threatening disease.."Dengue is a mosquito-borne infection caused by a flavivirus.
Dengue fever is continuous or "saddleback" with a break on 4 th or 5 th day and then recrudescence; usually lasts 7-8 days Classical dengue fever is characterized by the onset of fever, malaise, headache, facial flushing, retro bulbar pain that worsens on eye movements, conjunctival suffusion and severe back ace, which is a prominent symptom. Lymphadenopathy, petechiae on the soft palate and transient morbilliform skin rashes may also appear on the limbs with subsequent spread to involve the trunk Desquamation occurs. Cough is uncommon. Dengue fever syndrome is characterized by capillary leak syndrome, thrombocytopenia, hemorrhage, hypotension, and shock. It is characteristically a disease of children occurring most commonly in South-East Asia. Over 100 million cases occur every year in the tropics with over 10,000 deaths from dengue hemorrhagic fever. Previously, dengue was seen in small children and DHF/DSS in children 2-15 years old, and most frequently in those 16-45 years of age or older in whom severe organ dysfunction is more common. Other epidemiological changes include the spread of dengue into rural communities and greater case fatality in women.
Like malaria epidemic, dengue fever epidemics depend on temperature.Dengue and chicken guinea are two important viruses causing febrile illness syndrome.
I. Allen J.Cann, Principles of Molecular Virology,5 th.Ed, Elsevier,2012
II. Kenneth J Ryan,C.George Ray, Nafees Ahmed,W.Lawrence Drew, James,J.Plourde, Sherris Medical Microbiology,5 th Ed,Mc.Graw.Hill,2010
III. Simmons CP,Farrar JJ,Nguyen VV,et al.Dengue.Eng.J.Med.2012;366;1423-33
IV. Hunsperger EA,Duarte Dos Santos CN et al.Rapid and accurate interpretation of dengue diagnostics in the context of dengue vaccination implementation viewpoints and guidelines issued from an experts group consultation..PLos.Negl.Trop.Dis.2017;11 e0005719.
V. Priamvada I,Cho A,Onlamoon,et al.B-cell responses during secondary dengue virus infection are dominated by highly cross-reactive,memory-derivedplasmablasts.J.Virol,2016;90:5574-85
VI. Malvige GN,Fernando S,,Fernando DJ,,et al,Dengue viral infections.Post.grad.Med..J,2004;80;588-601
VII. Graham Simmons,Mars stone and Michael P.Busch,Arbovirus diagnostics;From bad to worse due to expanding Dengue virus vaccination and Zika virus epidemics,,Clinical infectious diseases,Infectious disease society of America,2018;66-1181
VIII. Malavige GN,Fernando DJ, Seneviratne SI,Dengue viral infections.Postgrad.Med.J,2004;80(948);588-601
IX. De Macedo FC, Nicole AF, Cooper LD, et al. Histologic, Viral and molecular correlates of dengue fever infection of the liver using highly sensitive immunohistochemistry.Diagn.Mol.Pathol.2006;15;223-228
X. Brady OJ,Gething PW,Bhatt S, et al. refining the global spatial limits of dengue virus transmission by evidence based consences.PLoS Negl..Trop.Dis,2012;6(8);e1760.
XI. Bhatt S,Gething PW,Brady OJ,et al.The global distribution and burden of dengue.Nature 2013;496(7446);504-7
XII. Brady O J, Gething PW, Bhatt S, Refining the global spatial limits of dengue virus transmission by evidence-based consensus.PLoS.Negl.Trop.Dis 2012 ;6(8);e 1760
XIII. Gubler D J, O0i E E,Vasudevan SG,Farrar J,Dengue and dengue hemorrhagic fever,Wallingford,UK;CAB International;2014
XIV. Ritchie SA.Dengue vector bionomics; why. Ades egypt is such a good vector In. Gubler D0i EE, Vasudevan S, FarrarJ.editors Dengue and dengue hemorrhagic fever,2 nd ed, Wallingford, UK, CAB International, 2014 pp455-80
XV. Hoffman AA, Montgomery BL, Popovici J, et al.Successful establishment of Wolbachia in Ades populations to suppress dengue transmission.Nature.2011,476,454-7
XVI. WHO.Guidelines on the quality,safety and efficacy of the dengue tetravalent vaccines(live,attenuated).Available at;www.who.int/biological/vaccines/dengue _DB_5 April,2012.accessed 2016.
XVII. I’Azou M,Mourean A,Sarti E,et al.CYD 15.primary study group symptomatic dengue in children in 10Asiaan and Latin American countries. N.Eng.J.Med,2016,374:1155-66
XVIII. WHO,world malaria report htpp//www.who.int/malarial publication/world report.2013/02/09/2014
XIX. White N J,Pukrittayakamee SHien TT,Faiz MA,Mokuolu OA,Dunlop AM,Malaria,Lancet 2014,383;723-35
XX. Alan J.Cann.Principles of molecular biology 5th Edn,2012-Printed in China
XXI. Brown DM,James AA,;Dengue vector control;New approaches;InGubler D;O0i EE,Vasudevan S,Farrar.J. editors.Dengue and Dengue hemorrhagic fever.Walling fordUk CAB international,2014;p519-36
XXII. Anonymous "Etymologia: dengue". 2006, Emerg. Infec. Dis. 12 (6): 893.
XXIII. Gubler DJ,. "Dengue and Dengue Hemorrhagic Fever". 1996,Clin. Microbiol. Rev. 11(3): 480–96.
XXIV. Henchal EA, Putnak JR "The dengue viruses". Clin. Microbiol.,1990, Rev. 3 (4): 376–96.
XXV. Fields,Virology,6 th ed,wolterkluwer,2013,Clinical and pathologic syndromes of the flaviviruses
XXVI. Halstead SB Dengue (Tropical Medicine: Science and Practice).2008, River Edge, N.J: Imperial College Press. pp. 1–10
XXVII. Barrett AD, Stanberry LR ,Vaccines for biodefense and emerging and neglected diseases.2009, San Diego: Academic. pp. 287–323
XXVIII. Sampath A, Padmanabhan R (January ,"Molecular targets for flavivirus drug discovery".2009, Antiviral Res. 81 (1): 6–15.
XXIX. Noble CG, Chen YL, Dong H, et al. . "Strategies for development of Dengue virus inhibitors".2010 Antiviral Res. 85 (3): 450–62.
XXX. Center for Disease Control and Prevention. "Chapter 5 – Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF)". 2010 Yellow Book. Retrieved 2010-12-23.
XXXI. Chen LH, Wilson ME,. "Dengue and chikungunya infections in travelers".2010, Curr. Opin. Infect. Dis. 23 (5): 438–44.
XXXII. .Kyle JL, Harris E, Global spread and persistence of dengueAnnu.Rev. Microbiol 2008;62;71-92
a. 33. Whitehorn J, Farrar J (2010). "Dengue". Br. Med. Bull. 95: 161–73. doi:10.1093/bmb/ldq019. PMID 20616106.
b. WHO (2009), pp. 14–16
XXXIII. Geo.F.Brooks, Karen C, Caroll, Janet S, Butel, Stephen A,Morse,Timothy.A,Mietzner, Melneck&adelbery's, Medical Micro,26 the Ed, Lange,2010
XXXIV. Dow D, Mora E, the maximum potential market for dengue drugs V 1.0Anti Viral Res;2012;96(2);203-12
XXXV. Barrett, ADT. Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease. Vaccine 2017; 35(44): 5951-5955
XXXVI. Hurre MR,N T Marianneau, P.et al. Liver histopathology biological correlates in five cases of fatal dengue fever in Vietnamese children.Virchows.Arch.43;107-115,2001
XXXVII. Jessie K , Fong M Y, Devi S,et al. Localization of dengue virus in naturally infected human tissues,by immunohistochemistry and in situ hybridizationJ.inf.Dis189;1411-1418,2004
XXXVIII. Mayer SV, Tesh RB, Vasilakis N. The emergence of arthropod-borne viral diseases: A global prospective on dengue, chikungunya and zika fevers. Acta Tropica 2017; 166: 155-163.
XXXIX. Lin CF, Wan SW, Chen MC, Lin SC, Cheng CC, Chiu SC, Hsiao YL, Lei HY, Liu HS, Yeh TM, Lin YS. Liver injury Downloaded from caused by antibodies against dengue virus nonstructural protein 1 in a murine model. Laboratory Investigation 2008; 88(10): 1079-89.
XL. BlacksellSD,Commercial dengue rapid diagnostic tests to –point-of-careapplication;recent evaluations and future needs.J.Biotechnol.2012.
XLI. Senaratne TN,Noordeen F,Diagnosis of dengue in Sri lanka improvements to the existing state of the art in the island.Trans& Soc.Trop.Med.Hyg,2014;108:685-91
XLII. LeonellaF,Dana et al. Controversy and debate on dengue vaccine series,Journal of clinical epidemiology,2018
XLIII. Remy MM, Dengue fever: theories of immunopathogenesis and challenges for vaccination.Inflamm Allergy Drug Targets. 2014;13(4):262-74.
XLIV. Subedi D,Taylor –Robinson AW,Development of dengue vaccine in humans so,near.Yet so far SOJ.Vaccines.Res 2015;1:7
XLV. Sophi Yacob,Jeremy Farrar,Mansons tropical disease,23 rd ed,Elsavier
XLVI. Shushi Sharma,Kundan TandelSurabhi Danwe, et al.Simultaneous detection and serotyping of dengue infection using single tube multiplex CDC.Dengue real time RT-PCR from India,Virus Dis,2018 29(1):40-45
XLVII. . Pan American Health Organization Prevention and Control of Dengue in the Américas; Pan American Sanitary Conference; October 1–5, 2007.2007. Resolution CSP27.R15
How to Cite
Copyright (c) 2022 International Education and Research Journal (IERJ)
This work is licensed under a Creative Commons Attribution 4.0 International License.